SMT202500137T1 - (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-ossazepan-2-carbossammidi come inibitori di dipeptidil peptidasi i - Google Patents

(2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-ossazepan-2-carbossammidi come inibitori di dipeptidil peptidasi i

Info

Publication number
SMT202500137T1
SMT202500137T1 SM20250137T SMT202500137T SMT202500137T1 SM T202500137 T1 SMT202500137 T1 SM T202500137T1 SM 20250137 T SM20250137 T SM 20250137T SM T202500137 T SMT202500137 T SM T202500137T SM T202500137 T1 SMT202500137 T1 SM T202500137T1
Authority
SM
San Marino
Prior art keywords
oxazepane
carboxamides
phenylethyl
cyano
inhibitors
Prior art date
Application number
SM20250137T
Other languages
English (en)
Italian (it)
Inventor
Carl-Johan Aurell
Hans Roland LÖNN
Stephen Connolly
Steven Swallow
Staffan Po Karlsson
John Fritiof Pontén
Kevin James Doyle
De Poël Amanda Jane Van
Graham Peter Jones
David Wyn Watson
Jaqueline Anne Macritchie
Nicholas John Palmer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202500137(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SMT202500137T1 publication Critical patent/SMT202500137T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SM20250137T 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-ossazepan-2-carbossammidi come inibitori di dipeptidil peptidasi i SMT202500137T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24
EP20173862.2A EP3744714B1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Publications (1)

Publication Number Publication Date
SMT202500137T1 true SMT202500137T1 (it) 2025-05-12

Family

ID=52432834

Family Applications (3)

Application Number Title Priority Date Filing Date
SM20180058T SMT201800058T1 (it) 2014-01-24 2015-01-23 (2s) -n- [(1s)-1-ciano-2-feniletil]-1,4-ossazepan-2-carbossammidi come inibitori di dipeptidil peptidasi
SM20250137T SMT202500137T1 (it) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-ossazepan-2-carbossammidi come inibitori di dipeptidil peptidasi i
SM20200433T SMT202000433T1 (it) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-ossazepan-2-carbossammidi come inibitori di dipeptidil peptidasi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20180058T SMT201800058T1 (it) 2014-01-24 2015-01-23 (2s) -n- [(1s)-1-ciano-2-feniletil]-1,4-ossazepan-2-carbossammidi come inibitori di dipeptidil peptidasi

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM20200433T SMT202000433T1 (it) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-ossazepan-2-carbossammidi come inibitori di dipeptidil peptidasi

Country Status (39)

Country Link
US (18) US9522894B2 (enExample)
EP (4) EP4548972A3 (enExample)
JP (7) JP6469711B2 (enExample)
KR (1) KR102417684B1 (enExample)
CN (2) CN110483492B (enExample)
AP (1) AP2016009322A0 (enExample)
AR (1) AR099177A1 (enExample)
AU (4) AU2015208932C1 (enExample)
BR (1) BR112016016224B1 (enExample)
CA (1) CA2935625C (enExample)
CL (1) CL2016001889A1 (enExample)
CR (1) CR20160327A (enExample)
CY (2) CY1120049T1 (enExample)
DK (3) DK3097086T3 (enExample)
DO (1) DOP2016000175A (enExample)
EA (1) EA032794B1 (enExample)
ES (3) ES2658516T3 (enExample)
FI (1) FI3744714T3 (enExample)
HK (1) HK1225730B (enExample)
HR (3) HRP20180116T1 (enExample)
HU (3) HUE052421T2 (enExample)
IL (3) IL246614B (enExample)
LT (3) LT3744714T (enExample)
MX (1) MX368840B (enExample)
MY (1) MY194850A (enExample)
NO (1) NO2699580T3 (enExample)
NZ (2) NZ722063A (enExample)
PE (1) PE20161218A1 (enExample)
PH (1) PH12016501439A1 (enExample)
PL (3) PL3744714T3 (enExample)
PT (3) PT3097086T (enExample)
RS (3) RS56919B1 (enExample)
SG (2) SG11201606052TA (enExample)
SI (3) SI3323814T1 (enExample)
SM (3) SMT201800058T1 (enExample)
TW (1) TWI690517B (enExample)
UY (1) UY35963A (enExample)
WO (1) WO2015110826A1 (enExample)
ZA (2) ZA201605856B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
KR20240091302A (ko) * 2016-07-29 2024-06-21 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
PL3758708T3 (pl) * 2018-03-01 2025-03-31 Astrazeneca Ab Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
JP2021530513A (ja) * 2018-07-17 2021-11-11 インスメッド インコーポレイテッド 炎症性腸疾患を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
CN114599367A (zh) * 2019-10-23 2022-06-07 株式会社钟根堂 用于预防或治疗慢性阻塞性肺病(copd)的组合物
WO2022020245A1 (en) * 2020-07-20 2022-01-27 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
SMT202400510T1 (it) * 2020-08-26 2025-01-14 Haisco Pharmaceuticals Pte Ltd Derivato di nitrile che agisce come inibitore di dipeptidil peptidasi 1 e suo uso
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
MX2023006194A (es) 2020-12-04 2023-06-09 Reistone Biopharma Company Ltd Inhibidor de molecula peque?a de catepsina c y uso medicinal del mismo.
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CA3207466A1 (en) * 2021-02-05 2022-08-11 Lingyun Wu Fused ring derivatives containing 1,4-oxazepane
WO2022232573A1 (en) * 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
US20250049813A1 (en) * 2021-10-29 2025-02-13 Insmed Incorporated Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
CN116332937A (zh) * 2021-12-23 2023-06-27 杭州邦顺制药有限公司 二肽基肽酶ⅰ抑制剂及其用途
CN118475575A (zh) * 2022-01-11 2024-08-09 上海壹典医药科技开发有限公司 一种肽基腈类化合物及其应用
KR20240148350A (ko) * 2022-02-16 2024-10-11 인스메드 인코포레이티드 화농성한선염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드
TW202333739A (zh) 2022-02-22 2023-09-01 大陸商四川海思科製藥有限公司 二肽基肽酶1抑制劑多晶型物及其製備方法和用途
AU2023226548A1 (en) 2022-02-22 2024-10-03 Haisco Pharmaceuticals Pte. Ltd. Preparation method of nitrogen-containing heterocyclic compound
JP2025508792A (ja) 2022-02-22 2025-04-10 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ阻害化合物の塩及び結晶形態
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
TW202404961A (zh) 2022-06-07 2024-02-01 大陸商瑞石生物醫藥有限公司 苯并［ｃ］色滿化合物的可藥用鹽、其多晶型及用途
US20250353839A1 (en) * 2022-06-07 2025-11-20 Reistone Biopharma Company Limited Polymorph of benzo[c]chroman compound, preparation method therefor and use thereof
TW202413352A (zh) 2022-06-13 2024-04-01 日商模數探索股份有限公司 氮雜環烷基羰基環狀胺化合物
US20250250232A1 (en) 2022-07-06 2025-08-07 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
IL321931A (en) * 2023-01-06 2025-09-01 Insmed Inc New and reversible DPP1 inhibitors and their uses
EP4665717A2 (en) * 2023-02-15 2025-12-24 Insmed Incorporated Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors
AU2024241242A1 (en) * 2023-03-23 2025-11-06 Haisco Pharmaceuticals Pte. Ltd. Pharmaceutical composition containing dipeptidyl peptidase small molecule inhibitor
WO2025059526A1 (en) * 2023-09-15 2025-03-20 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
DE60131423T2 (de) 2000-09-08 2009-03-19 Prozymex A/S Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen
AU9419601A (en) 2000-10-06 2002-04-22 Tanabe Seiyaku Co Nitrogenous five-membered ring compounds
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
CN1315806C (zh) 2001-12-04 2007-05-16 霍夫曼·拉罗奇有限公司 取代的2－氨基－环烷烃甲酰胺和它们作为半胱氨酸蛋白酶抑制剂的用途
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
EP1975153A3 (en) 2003-05-30 2010-03-31 Prozymex A/S Protease inhibitors
WO2004110988A1 (en) 2003-06-18 2004-12-23 Prozymex A/S Protease inhibitors
JP5301152B2 (ja) 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
US20070286854A1 (en) 2004-04-28 2007-12-13 Bayer Healthcare Ag Diagnostics And Therapeutics For Diseases Associated With Dipeptidyl-Peptidase 1 (Dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
CA2572359C (en) 2004-06-29 2010-08-03 Nycomed Danmark Aps Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
CN101022799A (zh) 2004-07-19 2007-08-22 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
CN103285395A (zh) 2005-02-18 2013-09-11 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
AU2006265835B2 (en) 2005-06-30 2012-05-03 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
CA2680312A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
WO2009042187A1 (en) 2007-09-25 2009-04-02 Nektar Therapeutics Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
KR101805754B1 (ko) 2008-12-08 2017-12-07 먼디파머 인터내셔널 코포레이션 리미티드 단백질 수용체 티로신 키나아제 억제제의 조성물
WO2010114405A2 (en) 2009-04-01 2010-10-07 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
AU2010244218B2 (en) * 2009-05-07 2012-07-19 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
ES3017582T3 (en) 2010-04-07 2025-05-13 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
EA023168B1 (ru) 2011-02-11 2016-04-29 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Ингибитор катепсина с
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
EP2817310B1 (en) 2012-02-21 2018-03-21 Merck Patent GmbH 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
PT2840083T (pt) 2012-04-17 2017-11-08 Astellas Pharma Inc Composto heterocíclico aromático bicíclico azotado
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
EP2970230B1 (en) 2013-03-14 2019-05-22 Boehringer Ingelheim International GmbH Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
US8877775B2 (en) 2013-03-14 2014-11-04 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
KR102295740B1 (ko) 2013-03-14 2021-09-01 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 억제제로서 치환된 2-아자-바이사이클로[2.2.1]헵탄-3-카복실산(벤질-시아노-메틸)-아미드
US8871783B2 (en) 2013-03-14 2014-10-28 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin C
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
US10670594B2 (en) 2013-08-22 2020-06-02 Emory University Devices and methods related to airway inflammation
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
JP6408008B2 (ja) 2013-09-09 2018-10-17 プロザイメックス・アクティーゼルスカブＰｒｏＺｙｍｅｘ Ａ／Ｓ ジペプチジルペプチダーゼｉインヒビターとしてのペプチジルニトリル化合物
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (enExample) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
WO2015155709A1 (en) 2014-04-10 2015-10-15 Novartis Ag S1p modulator immediate release dosage regimen
CN106535877A (zh) 2014-05-15 2017-03-22 英斯梅德股份有限公司 用于治疗肺部非结核性分枝杆菌感染的方法
CN107075557B (zh) 2014-05-30 2021-07-06 香港大学 使用嗜中性粒细胞弹性蛋白酶和蛋白酶3作为诊断生物标志物的方法和组合物
WO2016016242A1 (en) 2014-08-01 2016-02-04 Boehringer Ingelheim International Gmbh Substituted oxetanes and their use as inhibitors of cathepsin c
BR112017003433B1 (pt) 2014-09-12 2023-11-14 Boehringer Ingelheim International Gmbh Inibidores espirocíclicos de catepsina c, composição farmacêutica e uso dos mesmos
BR112017009595A2 (pt) 2014-11-14 2017-12-19 Boehringer Ingelheim Int morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
DK3265452T3 (en) 2015-03-05 2020-06-08 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
KR20240091302A (ko) 2016-07-29 2024-06-21 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
CA3089240A1 (en) 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
PL3758708T3 (pl) * 2018-03-01 2025-03-31 Astrazeneca Ab Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
JP2021530513A (ja) 2018-07-17 2021-11-11 インスメッド インコーポレイテッド 炎症性腸疾患を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
EP4252844A3 (en) 2019-04-17 2023-12-06 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
BR112021024310A2 (pt) 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
WO2022232573A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
US20250049813A1 (en) 2021-10-29 2025-02-13 Insmed Incorporated Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
KR20240148350A (ko) 2022-02-16 2024-10-11 인스메드 인코포레이티드 화농성한선염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드

Also Published As

Publication number Publication date
AU2015208932C1 (en) 2017-05-25
CN110483492A (zh) 2019-11-22
SMT202000433T1 (it) 2020-09-10
PH12016501439B1 (en) 2017-02-06
CA2935625C (en) 2022-10-18
US11680049B2 (en) 2023-06-20
SG10201701056QA (en) 2017-03-30
PE20161218A1 (es) 2016-11-27
US11814359B2 (en) 2023-11-14
JP7714823B2 (ja) 2025-07-29
US20150210655A1 (en) 2015-07-30
US10287258B2 (en) 2019-05-14
US20230085620A1 (en) 2023-03-23
PT3744714T (pt) 2025-04-07
US20230116721A1 (en) 2023-04-13
US20240132455A1 (en) 2024-04-25
MX2016009349A (es) 2016-10-13
US12054465B2 (en) 2024-08-06
US11655221B2 (en) 2023-05-23
JP7336563B2 (ja) 2023-08-31
US11673872B2 (en) 2023-06-13
NZ734768A (en) 2022-09-30
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
RS66709B1 (sr) 2025-05-30
SG11201606052TA (en) 2016-08-30
DK3097086T3 (en) 2018-02-05
MY194850A (en) 2022-12-19
EP4548972A2 (en) 2025-05-07
PL3323814T3 (pl) 2020-10-19
ES3018635T3 (es) 2025-05-16
KR20160111470A (ko) 2016-09-26
TWI690517B (zh) 2020-04-11
WO2015110826A1 (en) 2015-07-30
HUE052421T2 (hu) 2021-04-28
JP2023156479A (ja) 2023-10-24
CL2016001889A1 (es) 2016-12-09
CY1123391T1 (el) 2021-12-31
US20240336582A1 (en) 2024-10-10
HRP20180116T1 (hr) 2018-03-23
JP2019070029A (ja) 2019-05-09
TW201612167A (en) 2016-04-01
AU2015208932A1 (en) 2016-07-28
US11673871B2 (en) 2023-06-13
AU2019202675B2 (en) 2020-05-28
PH12016501439A1 (en) 2017-02-06
US10669245B2 (en) 2020-06-02
EP3097086B1 (en) 2017-12-13
EP3097086A1 (en) 2016-11-30
SI3744714T1 (sl) 2025-05-30
RS60639B1 (sr) 2020-09-30
JP2025072423A (ja) 2025-05-09
US20230062646A1 (en) 2023-03-02
AU2015208932A8 (en) 2017-03-09
PL3097086T3 (pl) 2018-04-30
JP2021046423A (ja) 2021-03-25
LT3744714T (lt) 2025-04-10
AU2017200338A1 (en) 2017-02-02
EP3744714A1 (en) 2020-12-02
CN105980367B (zh) 2019-08-23
PL3744714T3 (pl) 2025-09-08
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
SI3097086T1 (en) 2018-04-30
SI3323814T1 (sl) 2020-10-30
ES2658516T3 (es) 2018-03-12
US9815805B2 (en) 2017-11-14
EP3323814B1 (en) 2020-05-13
HUE070606T2 (hu) 2025-06-28
SMT201800058T1 (it) 2018-03-08
KR102417684B1 (ko) 2022-07-05
CN110483492B (zh) 2023-07-21
CR20160327A (es) 2016-10-20
CN105980367A (zh) 2016-09-28
HK1225730B (en) 2017-09-15
HRP20250302T1 (hr) 2025-04-25
CA2935625A1 (en) 2015-07-30
JP2017503832A (ja) 2017-02-02
US11655224B2 (en) 2023-05-23
JP7628587B2 (ja) 2025-02-10
ZA201800431B (en) 2019-09-25
US20180251436A1 (en) 2018-09-06
US20210238152A1 (en) 2021-08-05
CY1120049T1 (el) 2018-12-12
EP3744714B1 (en) 2025-01-15
DK3744714T3 (da) 2025-04-07
US20230278969A1 (en) 2023-09-07
US20200247765A1 (en) 2020-08-06
BR112016016224A2 (enExample) 2017-08-08
US20230115170A1 (en) 2023-04-13
US11655222B2 (en) 2023-05-23
AU2017200338B2 (en) 2018-03-01
LT3097086T (lt) 2018-02-26
US11655223B2 (en) 2023-05-23
NZ722063A (en) 2017-09-29
AR099177A1 (es) 2016-07-06
AU2018202956B2 (en) 2019-05-09
JP2025157389A (ja) 2025-10-15
HRP20201147T1 (hr) 2020-12-11
ES2808060T3 (es) 2021-02-25
FI3744714T3 (fi) 2025-04-01
US20230028726A1 (en) 2023-01-26
AU2015208932B8 (en) 2017-03-09
US20170057938A1 (en) 2017-03-02
US11667615B2 (en) 2023-06-06
US9522894B2 (en) 2016-12-20
EP4548972A3 (en) 2025-06-25
HK1255870A1 (en) 2019-08-30
EA032794B1 (ru) 2019-07-31
NO2699580T3 (enExample) 2018-02-24
US11117874B2 (en) 2021-09-14
BR112016016224B1 (pt) 2023-02-23
US20230033573A1 (en) 2023-02-02
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
DOP2016000175A (es) 2016-08-15
PT3323814T (pt) 2020-08-05
JP2022096662A (ja) 2022-06-29
JP7157791B2 (ja) 2022-10-20
IL252836A0 (en) 2017-08-31
JP6469711B2 (ja) 2019-02-13
ZA201605856B (en) 2020-02-26
EP3323814A1 (en) 2018-05-23
US20230069044A1 (en) 2023-03-02
AU2019202675A1 (en) 2019-05-16
AP2016009322A0 (en) 2016-07-31
EA201691375A1 (ru) 2017-01-30
IL265611A (en) 2019-05-30
DK3323814T3 (da) 2020-08-03
AU2015208932B2 (en) 2017-02-16
AU2018202956A1 (en) 2018-05-17
US20200017455A1 (en) 2020-01-16
LT3323814T (lt) 2020-10-26
MX368840B (es) 2019-10-18
US20230250071A1 (en) 2023-08-10
JP6804570B2 (ja) 2020-12-23
US20230025351A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
IL265611A (en) (S2)–N–[S)1)–1–cyano–2–phenylethanyl]–1,4–oxazaphene–2–carboxamides as dipeptidyl peptidase 1 inhibitors
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
DK3265452T3 (en) Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
IL256347A (en) New thrombin inhibitors